Document is current
Any future updates will be listed below
-
Authors
Sethna, Zachary
Guasp, Pablo https://orcid.org/0000-0002-3655-916X
Reiche, Charlotte https://orcid.org/0009-0004-6449-8335
Milighetti, Martina https://orcid.org/0000-0003-4170-8796
Ceglia, Nicholas
Patterson, Erin
Lihm, Jayon
Payne, George
Lyudovyk, Olga
Rojas, Luis A. https://orcid.org/0000-0001-9218-4086
Pang, Nan
Ohmoto, Akihiro
Amisaki, Masataka https://orcid.org/0000-0003-4153-4036
Zebboudj, Abderezak https://orcid.org/0000-0002-4708-5211
Odgerel, Zagaa
Bruno, Emmanuel M. https://orcid.org/0000-0003-2885-1133
Zhang, Siqi Linsey https://orcid.org/0009-0001-4436-2746
Cheng, Charlotte
Elhanati, Yuval https://orcid.org/0000-0002-4354-8864
Derhovanessian, Evelyna
Manning, Luisa
Müller, Felicitas
Rhee, Ina
Yadav, Mahesh
Merghoub, Taha https://orcid.org/0000-0002-1518-5111
Wolchok, Jedd D.
Basturk, Olca https://orcid.org/0000-0003-2747-1366
Gönen, Mithat https://orcid.org/0000-0001-8683-8477
Epstein, Andrew S.
Momtaz, Parisa
Park, Wungki https://orcid.org/0000-0002-8006-3102
Sugarman, Ryan
Varghese, Anna M.
Won, Elizabeth
Desai, Avni
Wei, Alice C. https://orcid.org/0000-0002-2505-959X
D’Angelica, Michael I.
Kingham, T. Peter
Soares, Kevin C. https://orcid.org/0000-0002-0406-017X
Jarnagin, William R.
Drebin, Jeffrey
O’Reilly, Eileen M. https://orcid.org/0000-0002-8076-9199
Mellman, Ira https://orcid.org/0000-0002-6132-7299
Sahin, Ugur https://orcid.org/0000-0003-0363-1564
Türeci, Özlem
Greenbaum, Benjamin D. https://orcid.org/0000-0001-6153-8793
Balachandran, Vinod P. https://orcid.org/0000-0002-2956-223X
- License Information
-
More Information
Article History
Received: 5 April 2024
Accepted: 10 December 2024
First Online: 19 February 2025
Competing interests
: L.A.R., Z.M.S., B.D.G. and V.P.B. are inventors on patent applications related to work on antigen cross-reactivity and tracking vaccine-induced T cell clones. B.D.G. and V.P.B. are inventors on a patent application on neoantigen quality modelling. L.A.R. is an inventor of a patent related to oncolytic viral therapy. B.D.G. has received honoraria for speaking engagements from Merck, Bristol Meyers Squibb and Chugai Pharmaceuticals; has received research funding from Bristol Meyers Squibb, Merck and ROME Therapeutics; and has been a compensated consultant for Darwin Health, Merck, PMV Pharma, Shennon Biotechnologies, Synteny and Rome Therapeutics of which he is a co-founder. V.P.B. reports honoraria and research support from Genentech and research support from Bristol-Myers Squibb. A.S.E received royalties from Up-To-Date. A.V. reports research funding from Lilly, Verastem, BioMed Valley Discoveries, Bristol-Myers Squibb and Silenseed. A.C.W. reports the following: Histosonics, consulting and Ipsen, clinical trial funding. E.M.O. reports research funding to the institution from: Genentech/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, NIH/NCI, Digestive Care and Break Through Cancer; consulting via Data and Safety Monitoring Board (DSMB) for: Arcus, Alligator, Agenus, BioNTech, Ipsen, Merck, Moma Therapeutics, Novartis, Syros, Leap Therapeutics, Astellas, BMS, Fibrogen, Revolution Medicine, Merus Agios (spouse), Genentech-Roche (spouse), Eisai (spouse) and Servier (Spouse). J.D. owns stock in Alnylam Pharmaceuticals, Arrowroot Acquisition and Ionis Pharmaceuticals. T.M. is a co-founder and holds equity in IMVAQ Therapeutics; is a consultant for Immunos Therapeutics, ImmunoGenesis and Pfizer; has research support from Bristol-Myers Squibb, Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals, Peregrine Pharmaceuticals, Adaptive Biotechnologies, Leap Therapeutics and Aprea; and has patents on applications related to work on oncolytic viral therapy, alphavirus-based vaccine, neoantigen modelling, CD40, GITR, OX40, PD-1 and CTLA-4. J.D.W. is a consultant for Apricity, CellCarta, Ascentage Pharma, AstraZeneca, Bicara Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Dragonfly, Georgiamune, Imvaq, Larkspur, Psioxus, Recepta, Tizona and Sellas. J.D.W. receives grant and research support from Bristol-Myers Squibb and Sephora. J.D.W. has equity in Apricity, Arsenal IO, Ascentage, Imvaq, Linneaus, Georgiamune, Maverick and Tizona Therapeutics. W.P. reports research funding to institution from: Merck, Astellas, Miracogen and Amgen; consultancy or advisory board activity for: Astellas and EXACT Therapeutics; honoraria for Continuing Medical Education (CME) from: American Physician Institute and Integrity. O.T. and U.S. are co-founders, management board members and employees at BioNTech. E.D., L.M. and F.M. are employees at BioNTech. I.R., M.Y. and I.M. are employees at Genentech. The other authors declare no competing interests.
